Study details
Enrolling now
A Phase 1/2 Trial of SP-101 for Cystic Fibrosis (CF)
Spirovant Sciences, Inc.
NCT IDNCT06526923ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1/2
Target enrollment
15
Study length
about 2.3 years
Ages
18–65
Locations
4 sites in KS, MA, NY +1
What this study is about
This trial is testing a new treatment called SP-101 in adults with cystic fibrosis who cannot use CFTR modulators. The treatment will be given as part of a combination therapy with doxorubicin, and it will last 836 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take SP-101 and doxorubicin Cohort 1
- 2.Take SP-101 and doxorubicin Cohort 2
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
chemotherapy (Anthracycline chemotherapy; intercalates DNA and inhibits topoisomerase II)
Endpoints
Primary: Incidence and severity of adverse events
Body systems
Respiratory